Key result
Elevated plasma TMAO is linked to ~70% higher odds of prevalent atrial fibrillation.
Why the study?
The role of gut microbiota-derived trimethylamine N-oxide in the pathogenesis of atrial fibrillation remained uncertain.
Does gut microbial trimethylamine N-oxide (TMAO) generation increase the risk of atrial fibrillation in human subjects and mouse models?
Cross-Sectional (n=5,090)
No
Does gut microbial trimethylamine N-oxide (TMAO) generation increase the risk of atrial fibrillation in human subjects and mouse models?
Odds Ratio: 1.7 (95% CI 1.3–2.1)
p-value: p=<0.01
Gut microbial production of TMAO is independently associated with atrial fibrillation risk in humans and directly promotes AF in mouse models via autonomic dysfunction, highlighting the gut microbial TMAO pathway as a potential therapeutic target for AF prevention.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“Most current treatments for atrial fibrillation focus on managing the condition, but our findings suggest there may be an opportunity to intervene much earlier through diet.”
TMAO may represent a modifiable AF risk factor; prospective human trials are needed before microbial interventions are considered.
Gut microbiota-derived trimethylamine N -oxide (TMAO) plays a role in the pathogenesis of cardiovascular disease. The role of TMAO in the pathogenesis of atrial fibrillation (AF) remains uncertain. TMAO levels were quantified in plasma from serial subjects undergoing elective cardiac catheterizations (N=5090) and shown to independently associate with prevalent AF following adjustment for risk factors (TMAO adjusted odds ratio 1.7 [95% confidence interval 1.3-2.1]; P <0.01). Human cAMP response element modulator isoform IbΔC-X transgenic mice (CREM-IbΔC-X), a spontaneous mouse model of AF, supplemented with a TMAO diet developed AF sooner. C57BL/6J mice on and off a TMAO had more inducible AF via a transesophageal pacing study compared to chow controls. Dietary choline supplementation increased circulating TMAO levels and significantly accelerated AF onset in CREM-IbΔC-X mice ( P <0.01). Iodomethylcholine (IMC), the gut microbial CutC/D inhibitor that suppresses choline→TMA(O) metabolic transformation, reduced circulating TMAO levels ( P <0.0001) and choline induced AF onset ( P <0.01). Cecal metagenomic analyses showed that choline supplementation induced changes in microbial communities associated with AF, while many of these changes were attenuated by IMC. Choline supplementation promoted overall adverse atrial remodeling with left atrial dilation. Optical mapping studies showed that mice supplemented with choline exhibited reduced conduction velocity, shortened action potential duration at 80% repolarization, and decreased wavelength. TMAO inhibits muscarinic receptor 2 resulting in autonomic dysfunction that promotes AF. In summary, the gut microbial metabolite TMAO, independently associated with AF risk in subjects, enhances AF in multiple AF mouse models via autonomic dysfunction, and is a therapeutic target for prevention of AF.
No takes yet. Share an insight, caveat, or question.
Arjunan et al. (2026) conducted a cross-sectional in Atrial fibrillation (n=5,090). Elevated plasma trimethylamine N-oxide (TMAO) levels vs. Lower plasma TMAO levels was evaluated on Prevalent atrial fibrillation (OR 1.7, 95% CI 1.3-2.1, p=<0.01). Elevated plasma TMAO levels were independently associated with increased odds of prevalent atrial fibrillation (OR 1.7) in subjects undergoing elective cardiac catheterizations.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: